These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3622306)

  • 1. Influence of cyclandelate on in vitro red blood cell deformability.
    Hall DW; van den Hoven WE
    Drugs; 1987; 33 Suppl 2():30-40. PubMed ID: 3622306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium modulation and clinical effect. Profile of cyclandelate.
    Timmerman H
    Drugs; 1987; 33 Suppl 2():1-4. PubMed ID: 3622303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of cyclandelate on Ca++ translocation in human platelets.
    Akkerman JW; van den Hoven WE
    Drugs; 1987; 33 Suppl 2():53-9. PubMed ID: 3622308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human platelet functions by cyclandelate.
    van den Hoven WE; Hall DW
    Drugs; 1987; 33 Suppl 2():41-52. PubMed ID: 3304954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cyclandelate on prostacyclin release and cytosolic free calcium concentrations in human endothelial cells.
    van Hinsbergh VW
    Drugs; 1987; 33 Suppl 2():60-6. PubMed ID: 3304955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclandelate as a calcium modulating agent in rat cerebral cortex.
    Bast A; Leurs R; Timmerman H
    Drugs; 1987; 33 Suppl 2():67-74. PubMed ID: 3040372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Red blood cell deformability in diabetes mellitus: effect of phytomenadione.
    Sabo A; Jakovljević V; Stanulović M; Lepsanović L; Pejin D
    Int J Clin Pharmacol Ther Toxicol; 1993 Jan; 31(1):1-5. PubMed ID: 8444511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication.
    Dawson DL; Zheng Q; Worthy SA; Charles B; Bradley DV
    Angiology; 2002; 53(5):509-20. PubMed ID: 12365857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of pentoxifylline in endotoxin-induced alterations of red cell deformability and whole blood viscosity in the neonate.
    Mollitt DL; Poulos ND
    J Pediatr Surg; 1991 May; 26(5):572-4. PubMed ID: 2061813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclandelate: calcium modulation and clinical effects. Proceedings of a symposium. Helsinki, 14-15 November, 1986.
    Drugs; 1987; 33 Suppl 2():1-141. PubMed ID: 3622302
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclandelate. An inhibitor of cholesterol esterification.
    Middleton B; Cacciaguerra F; White D
    Drugs; 1987; 33 Suppl 2():75-9. PubMed ID: 3622309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of alcoholic hyperlipoproteinemias on the deformability and viscosity of erythrocytes].
    Goebel KM; Goebel FD; Lanser KG
    Schweiz Med Wochenschr; 1984 Oct; 114(40):1386-8. PubMed ID: 6494873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclandelate and a number of its metabolites inhibit discocyte-echinocyte transformations of human erythrocytes.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():26-30. PubMed ID: 6430318
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of flunarizine on erythrocyte suspension viscosity under conditions of extreme hypoxia, low pH, and lactate treatment.
    Kavanagh BD; Coffey BE; Needham D; Hochmuth RM; Dewhirst MW
    Br J Cancer; 1993 Apr; 67(4):734-41. PubMed ID: 8471430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory action of cyclandelate and a number of its metabolites on cyclic AMP phosphodiesterase.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():20-5. PubMed ID: 6331483
    [No Abstract]   [Full Text] [Related]  

  • 16. Reduced red cell deformability associated with blood flow and platelet activation: improved by dipyridamole alone or combined with aspirin.
    Bozzo J; Hernández MR; Ordinas A
    Cardiovasc Res; 1995 Nov; 30(5):725-30. PubMed ID: 8595619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modes and mechanisms of action of vasoactive drugs and especially of cyclandelate.
    Timmerman H
    Br J Clin Pract Suppl; 1984; 34():10-9. PubMed ID: 6430317
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of aldose reductase from rat nervous tissue by metabolites of cyclandelate.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():31-3. PubMed ID: 6430320
    [No Abstract]   [Full Text] [Related]  

  • 19. Role molecular signaling pathways in changes of red blood cell deformability.
    Muravyov AV; Tikhomirova IA
    Clin Hemorheol Microcirc; 2013; 53(1-2):45-59. PubMed ID: 22951624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human platelet aggregation by cyclandelate.
    Van den Hoven WE; Hall DW
    Br J Clin Pract Suppl; 1984; 34():34-8. PubMed ID: 6430321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.